May 22, 2008

QRx Pharma Releases Additional  Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy


For further information please contact:
Chris Campbell, Chief Financial Officer
+612 9492 8021 (office) +61 401 988 444 (mobile)


About QRxPharma
QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused
on the development and commercialisation of new treatments for pain management and
central nervous system (CNS) disorders. Based on a development strategy which focuses
on enhancing and expanding the clinical utility of currently marketed compounds, the
Company’s product portfolio includes both late and early stage clinical drug candidates
with the potential for reduced risk, abbreviated development paths, improved safety and
patient outcomes, and greater market value for direct commercialisation in the US as well
as potential for strategic partnerships abroad. QRxPharma’s lead compound, Q8003IR,
began its Phase III development program in November, 2007. The Company’s
preclinical and clinical pipeline includes other technologies in the fields of pain
management, neurodegenerative disease and venomics. For more information:
www.QRxPharma.com.